UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in
neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve
the clinical efficacy in the real world.